A new study published in The Korean Journal of Gastroenterology evaluated the efficacy of rifaximin in reducing bloating associated with functional gastrointestinal disorders (FGIDs). This study retrospectively assessed 63 patients who were treated with rifaximin (800-1,200 mg/day for 5 to 14 days) for FGIDs with bloating or gas-related symptoms between 2007 and 2013 at Seoul National University Bundang Hospital. The mean age of the patients was 56.8±14.2 years; 49.2% were females. Response was recorded when the symptoms were reduced by at least 50%, at the follow-up after treatment cessation. Among the patients included 20.6% had irritable bowel syndrome (IBS) with constipation, 9.5% had IBS with diarrhea, 4.8% had mixed IBS, 23.8% had functional dyspepsia, and 12.7% had functional bloating, according to Rome III criteria. While of the 51 subjects who were followed-up, 58.8% had adequate relief of global FGID symptoms and 51.0% experienced improvement of abdominal bloating after rifaximin treatment. On the other hand, the proportion of females was slightly higher in non-response group than in the response group. All other characteristics were comparable between the two groups. The findings suggested that rifaximin may be beneficial for abdominal bloating in patients with FGIDs.